Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Aikido Pharma Inc is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. Our diverse pipeline of therapeutics includes therapies for prostate, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results. For more information, get in touch with Aikido Pharma Inc by calling us at 212-745-1373.  

The University of Texas at Austin has identified a new drug “DHA-dFdC” that has shown positive results in preclinical studies, inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.

DHA-dFdc is a new compound that holds promising indications of becoming the next generation of chemotherapy treatment for advanced pancreatic cancer
- Inhibits pancreatic cancer cell growth (up to 100,000-fold more potent that gemcitabine, a current standard therapy)
- Has documented efficacy against pancreatic tumors in a clinically relevant transgenic mouse model
- Overcomes tumor cell resistance to current chemotherapeutic drugs
- Is well tolerated in preclinical toxicity test
- Has demonstrated activities against other cancers (e.g. leukemia, lung, melanoma)
- May stimulate immunogenic cell death to activate host anti-tumor immunity